drugset
drugset / Trial / NCT04965831

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

NCT04965831 ↗

Phase 2 Unknown 40 enrolled Tianjin Medical University Cancer Institute and Hospital Allist Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.

Timeline

Start
2021-08-01
Primary completion
2023-03-01
Completion
2026-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Firmonertinib Small molecule 80 mg —

Indications

lung adenocarcinoma